TRiP research group

TRiP

We are performing a number of clinical trials of phase I and II in healthy volunteers and in early psychosis, currently focussing on cannabidiol as a potential new antipsychotic.

We are also active in other areas of clinical trials. In addition, we are working hard to initiate clinical trials in patients at later stages of psychosis and suffering other indications, where cannabinoids may prove useful.

Our trials follow highest ethical and regulatory standards and are approved and controlled by the responsible competent authorities and ethic committees in compliance with legal and international standards of Good Clinical Practise.

At the present stage, we do by no means recommend the use of cannabinoid drugs in psychiatric disorders outside of controlled clinical trials or support respective aims.